Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment
Journal of Clinical Medicine · 16.05.2026 · 15 (10) · 3845
DOI: 10.3390/jcm15103845 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.05.2026. Verfasst von Daniela Pastore und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Asthma is a heterogeneous chronic airway disease characterized by inflammation, airflow obstruction, hyperresponsiveness, and remodeling. Severe eosinophilic asthma is driven by eosinophilic inflammation, which contributes to tissue damage, recurrent exacerbations, and progressive impairment of airway structure and function. Eosinophils play a central role through the release of cytokines, cytotoxic granule proteins, and extracellular traps, and their persistence in the airways is sustained by type 2 inflammatory pathways, particularly interleukin-5-mediated signaling. A better understanding of eosinophil biology has promoted the development of targeted therapies, including anti-interleukin-5/interleukin-5 receptor agents and biologics that indirectly modulate eosinophilic inflammation, such as anti-interleukin-4 receptor alpha and anti-thymic stromal lymphopoietin antibodies.
Aim
This narrative review summarizes the immunopathology of eosinophilic asthma and links eosinophil biology to current and emerging pharmacological strategies. We discuss biologics that directly target the IL-5/IL-5 receptor axis, as well as agents that indirectly modulate eosinophilic inflammation, including IL-4 receptor alpha and TSLP blockade. We also review the clinical positioning of available biologics, focusing on blood eosinophils, FeNO, exacerbation history, oral corticosteroid exposure, lung function, type 2 comorbidities, treatment response, remission and switching.
Conclusions
Overall, eosinophilic inflammation remains a central therapeutic target and a key component of precision medicine in severe asthma, but biologic selection should be individualized and reassessed through multidomain clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
- Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
- Department of Respiratory Diseases, Annunziata Hospital, 87100 Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
ORCID-Profile: Chiara Lupia, Emanuela Chiarella, Giuseppe Mazza, Giuseppe Neri, Federico Longhini, Girolamo Pelaia, Corrado Pelaia
Zitieren
APA
Pastore, D., Lupia, C., Chiarella, E., Piazzetta, G. L., Mazza, G., Neri, G., Petrone, A., Bruni, A., Longhini, F., Garofalo, E., Pelaia, G., & Pelaia, C. (2026). Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment. Journal of Clinical Medicine, 15(10), 3845. https://doi.org/10.3390/jcm15103845
Vancouver
Pastore D, Lupia C, Chiarella E, Piazzetta GL, Mazza G, Neri G, et al. Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment. Journal of Clinical Medicine. 2026;15(10):3845. doi:10.3390/jcm15103845
BibTeX
@article{Pastore2026,
author = {Pastore, Daniela and Lupia, Chiara and Chiarella, Emanuela and Piazzetta, Giovanna Lucia and Mazza, Giuseppe and Neri, Giuseppe and Petrone, Albino and Bruni, Andrea and Longhini, Federico and Garofalo, Eugenio and Pelaia, Girolamo and Pelaia, Corrado},
title = {Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {10},
pages = {3845},
doi = {10.3390/jcm15103845}
}
EUVIMED